UK-based liquid biopsy company Angle plc has reported positive results from its first large-scale study using the Parsortix system to detect ovarian cancer. The company completed two independent studies, at the University of Texas MD Anderson Cancer Center and at the University of Vienna in Europe.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?